With the future of mRNA vaccines secure, an expert discusses the benefits of vaccine platform diversification.

The experimental mRNA vaccine prevented 60% to 67% of flu infections, while the conventional vaccine prevented 44% to 54% of ...

The new trial, funded by Pfizer, compared the company’s mRNA shot to Fluzone, one of the most widely used seasonal flu ...

The mRNA platform offers the advantage of faster vaccine production, which could allow more time to decide on which flu strains to cover.

A newly developed mRNA-based flu vaccine is almost 35 per cent more effective against the most common form of influenza, ...

The new study involved taking a fresh look at the "Altamura Man," which is an exceptionally well-preserved Neanderthal ...

A team of researchers at the Broad Institute, led by gene-editing pioneer David Liu, has developed a new genome-editing ...

Moderna's $140 million investment in Norwood, Massachusetts, aims to complete its U.S. manufacturing loop, enhancing ...

The new plant will allow the company to execute end-to-end clinical- and commercial-stage production of its mRNA medicines.

For the last several months, reports about bird flu have largely quieted -- until now. In the first human bird flu case in the U.S. since February, an older adult in Washington state was hospitalized ...

The field of immunology has recently seen a surge of interest in the roles of circular RNAs (circRNAs) and microRNAs (miRNAs) ...

Despite the success of immune checkpoint inhibitors in revolutionizing oncology, their benefits remain limited to a small ...